The penetration of anti-cancer agents into and throughout solid tumors is widely recognized as a major limitation to their effectiveness. WellThera’s proprietary platform technology, BUS-DDS, has been developed to enable a step change in the therapeutic index of anti-cancer agents by increasing their dose and distribution within solid tumors without any development costs or delays associated with their reformulation.
This approach can be designed to seamlessly fit into the existing clinical workflows.
“Theranostics Bubble” is supplied as a freeze-dried formulation. At the time of use, simply add 2 mL of water for injection and shake gently.